This also explains the lack of Igβ-targeting chimeric antigen receptor T cell studies in CLL therapy, although they show high efficacy in other B cell lymphomas, such as the diffuse large B cell lymphoma (DLBCL) (51). Here, CD79B is linked to diffuse large B-cell lymphoma.